Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Acupuncture Needles Market Size & Share 2026-2035
Report ID: GMI5637
|
Published Date: September 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Download Free PDF
Acupuncture Needles Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Acupuncture Needles Market Size
The global acupuncture needles market was valued at USD 306.6 million in 2025 and is projected to grow from USD 328.8 million in 2026 to USD 647.8 million by 2035, expanding at a CAGR of 7.8%, according to the latest report published by Global Market Insights Inc.
Acupuncture Needles Market Key Takeaways
Market Leader: SEIRIN Corporation led with over 20% market share in 2025.
Leading Players: Top 5 players in this market include SEIRIN Corporation, Boen Healthcare, 3B Scientific GmbH, Suzhou Hualun Medical, MeyerDC, which collectively held a market share of 80% in 2025.
Market expansion is linked to the growing volume of chronic and musculoskeletal conditions for which acupuncture is used as a complementary pain-management intervention. The number of people living with diabetes increased from 200 million in 1990 to 830 million in 2022, with prevalence rising faster in low- and middle-income countries. [1]World Health Organization, Diabetes, November 2024, who.int More broadly, noncommunicable diseases, including cardiovascular disease, cancer, chronic respiratory disease, and diabetes, remain a major global health burden.
Demand is also supported by the clinical burden of musculoskeletal conditions. Around 1.71 billion people live with musculoskeletal conditions worldwide, while low back pain is the leading cause of disability in 160 countries. [2]World Health Organization, Musculoskeletal health, who.int These conditions do not automatically translate into acupuncture utilization; however, they enlarge the pool of patients and providers assessing non-pharmacological options for pain control, rehabilitation, and functional recovery.
GMI Analyst View
The market's growth profile reflects a durable clinical-demand base rather than a single treatment trend. Chronic-disease prevalence broadens the addressable patient pool, while musculoskeletal pain creates a more direct and repeat-use setting for needle-based treatment. The commercial consequence is that suppliers must compete on dependable clinical quality, sterility, insertion performance, and availability across both institutional and outpatient channels.
The forecast also depends on the market's ability to convert interest in complementary care into recurring treatment protocols. Conditions involving chronic pain and rehabilitation support repeat visits and ongoing needle consumption, but adoption remains sensitive to practitioner confidence, reimbursement boundaries, and patient safety perceptions. This favors manufacturers that can serve established clinical settings while adapting product formats to home-care and supervised self-administration opportunities.
Key Drivers
Surge in the prevalence of chronic diseases
The rising burden of chronic disease creates a larger population requiring long-term symptom management and rehabilitation support. Diabetes prevalence increased more than fourfold between 1990 and 2022. Although chronic disease prevalence does not itself establish treatment selection, it expands the clinical contexts in which acupuncture may be evaluated alongside conventional care, particularly where pain, mobility limitations, or treatment-related discomfort persist.
Increasing number of people suffering from muscular pain
Muscular pain is the largest application segment, accounting for 36.18% of market revenue in 2025. The segment's scale is consistent with the broad prevalence of musculoskeletal disorders and the disproportionate disability burden associated with low back pain. Needles used in pain treatment must balance insertion control with patient comfort because repeat treatment adherence depends on the clinical experience as much as the initial treatment decision.
Growing adoption of acupuncture in rehabilitation of COPD patients
Evidence on acupuncture in chronic obstructive pulmonary disease has created a more defined rehabilitation use case beyond pain treatment. A 2024 study reported that acupuncture may improve exercise capacity in COPD through reductions in dyspnea and leg fatigue, with treatment of accessory respiratory muscles associated with improved muscle blood flow and lower excessive muscle tension. [3]BMC Complementary Medicine and Therapies, Effect of acupuncture on exercise capacity in COPD mediated by improvements of dyspnea and leg fatigue, 2024, link.springer.com A systematic review of seven studies also found statistically significant improvements in maximum inspiratory pressure and accessory respiratory muscle mobilization when acupuncture was added to standard COPD treatment. These findings support a complementary rehabilitation role, rather than a substitute for established respiratory care.
Rising awareness regarding alternate therapies among the population base
Growing familiarity with complementary therapies can increase patient willingness to discuss acupuncture with clinicians, particularly in chronic-pain and rehabilitation settings. The commercial effect is strongest where awareness is accompanied by qualified practitioners, consistent treatment standards, and access through hospitals or clinics. Home-care demand may create an additional opportunity, but it remains dependent on appropriate supervision, product safety, and local treatment practices.
Key Restraints
Adverse effects related to acupuncture treatment
Safety concerns can constrain treatment uptake when patients, providers, or payers perceive the procedure as inadequately controlled. A systematic review found that 9.31% of patients undergoing an acupuncture treatment series experienced at least one adverse event, with bleeding, pain, or flare at the needle site representing about half of reported events. Most events are minor, while serious adverse events were estimated at approximately 0.04–0.08 per 10,000 treatments; reported serious outcomes include pneumothorax, nerve injury, infection, and needle breakage.
This distinction matters commercially. The low incidence of serious events does not remove the need for sterile, consistent needles and competent clinical technique. Instead, it concentrates procurement attention on product integrity, packaging, training, and adherence to appropriate treatment protocols.
Lack of reimbursement scenario
Reimbursement limits can restrict acupuncture use even where patient demand and clinical interest are present. In the U.S., Medicare Part B coverage is limited to chronic low back pain, allowing up to 12 visits within 90 days and no more than 20 visits annually; other indications are not covered, and licensed acupuncturists cannot bill Medicare directly. [4]Medicare.gov, Acupuncture coverage, 2024, medicare.gov CMS policy similarly specifies coverage only for chronic low back pain under National Coverage Determination 30.3, leaving other indications non-covered.
The reimbursement gap particularly affects applications such as migraine, arthritis, sports rehabilitation, and respiratory support, where clinical use may be considered but payment pathways are less established. Providers serving self-pay patients may remain active buyers, but demand is more exposed to household affordability and local practice patterns.
GMI Analyst View
The market is shaped by an asymmetry between clinical need and payment support. Chronic pain, musculoskeletal disability, and rehabilitation use cases provide a substantial demand foundation, yet the conversion of that need into paid treatment depends on safety assurance and reimbursement eligibility. Suppliers therefore face a market in which clinical credibility and cost-to-serve discipline are more important than broad consumer awareness alone.
COPD rehabilitation illustrates the opportunity and constraint. Published evidence supports potential improvement in exercise capacity and respiratory symptoms when acupuncture complements standard care, but reimbursement policies remain concentrated in narrower pain indications. Manufacturers able to support hospital and clinic protocols with reliable disposable products are better positioned than those relying solely on elective consumer demand.
Acupuncture Needles Market Segment Analysis
By Product
Disposable needles held a 57.22% share of the market in 2025 and are projected to grow at a 7.98% CAGR through 2035. Their lead reflects the importance of sterility, single-use protocols, and operational consistency in high-throughput hospitals and clinics. Reusable needles represented 42.78% of the market and are expected to expand at a 7.60% CAGR, retaining relevance where practitioners prioritize established treatment routines and manage reprocessing requirements.
SEIRIN's J-Type product illustrates the product attributes supporting disposable demand: it uses stainless steel, is sterile and disposable, and emphasizes low-resistance insertion through its Light Touch Insertion technology. [5]SEIRIN, J-Type, global.seirin.jp In institutional procurement, these features address both patient experience and the need to standardize treatment delivery across practitioners.
By Material
Stainless steel accounted for 44.41% of revenue in 2025 and is forecast to record an 8.06% CAGR. Its position is underpinned by its balance of strength, manufacturability, and suitability for sterile disposable formats. Gold held a 21.50% share, silver represented 23.88%, and other materials accounted for 10.21% of the market. Material selection remains linked to practitioner preference, product design, handling characteristics, and the intended clinical setting.
A 3B Scientific Millennia needle pack combines surgical stainless steel with a silver spiral handle and emphasizes higher tensile strength for smooth insertion. [6]3B Scientific, Millennia 5 Needle Pack, 3bscientific.com Such designs show that material competition is not limited to the needle shaft; handle construction and insertion behavior can differentiate products in practitioner-led channels.
By Application
Muscular pain represented 36.18% of the market in 2025 and is expected to grow at a 7.87% CAGR. Migraine accounted for 12.30%, sports injuries for 20.34%, arthritis for 18.87%, and other applications for 12.31%. Sports injuries are projected to post the fastest application CAGR, at 8.14%, reflecting their alignment with rehabilitation-oriented treatment settings.
The application mix favors suppliers that can support varying treatment frequencies and needle specifications without fragmenting inventory. Pain and arthritis treatment can generate sustained demand through chronic-care pathways, whereas sports injury treatment may require responsive availability through rehabilitation and outpatient networks.
By End Use
Hospitals accounted for 44.37% of the market in 2025 and are projected to expand at a 7.94% CAGR. Clinics represented 32.40% and are forecast to record the fastest end-use growth, at 8.06%, while other end users held 23.22%. Hospital demand benefits from established procurement processes and the ability to embed acupuncture in multidisciplinary pain, rehabilitation, and specialty-care services.
Clinics are likely to be the more adaptive channel for treatment formats aimed at chronic pain and repeat outpatient care. The developing home-care opportunity may widen access over time, but it is unlikely to displace clinical channels where practitioner technique, safety oversight, and individualized treatment selection remain central.
GMI Analyst View
Disposable stainless-steel products sit at the commercial center of the market because the format aligns sterility, workflow efficiency, and insertion reliability with the needs of hospitals and clinics. Product differentiation is therefore moving beyond material labels toward measurable handling characteristics, packaging quality, and consistency across treatment sessions.
The fastest growth is expected in sports injuries and clinics, while muscular pain and hospitals retain the largest revenue positions. This combination creates two distinct routes to scale: suppliers can serve high-volume institutional accounts with standardized disposable formats, or build flexible portfolios for outpatient practitioners treating repeat pain and rehabilitation cases. A product strategy that treats all applications as interchangeable would miss these differences in procurement behavior and treatment cadence.
Acupuncture Needles Market Regional Analysis
North America
North America accounted for USD 76.63 million in 2025 and is projected to reach USD 160.21 million by 2035, advancing at a 7.71% CAGR. The U.S. represented 92.75% of the regional market in 2025, while Canada accounted for 7.25%. Chronic pain creates a substantial demand base: 20.9% of U.S. adults, or 51.6 million people, experienced chronic pain in 2021, and 6.9%, or 17.1 million people, experienced high-impact chronic pain. [7]Centers for Disease Control and Prevention, Chronic Pain Among Adults - United States, 2019-2021, April 2023, cdc.gov
The U.S. market also demonstrates the constraint imposed by selective reimbursement. Medicare coverage is limited to chronic low back pain, directing providers toward self-pay, private-pay, and condition-specific treatment models for many other applications. Canada remains part of the regional scope, but its smaller market size makes distributor reach and clinic access particularly important.
Europe
Europe accounted for 22.20% of global revenue in 2025, equivalent to approximately USD 68.06 million. Germany, the UK, France, Spain, Italy, and the Netherlands comprise the regional country scope. The region's chronic-disease burden is substantial: the International Diabetes Federation estimates that 66 million people in Europe have diabetes, representing a prevalence of 9.8%, and projects a 10% increase by 2050.
Germany provides a specific pain-demand indicator. The BURDEN 2020 study found that 61.3% of respondents reported back pain and 45.7% reported neck pain during the preceding 12 months, with women reporting back pain significantly more often than men. The commercial implication is a large clinical rationale for pain-management services, although payer policy and national practice frameworks will continue to determine how consistently demand translates into reimbursed needle use.
Asia Pacific
Asia Pacific led the global market with a 41.29% share in 2025, equivalent to approximately USD 126.59 million. China, India, Japan, Australia, and South Korea form the regional country scope. The region combines established acupuncture practice with broad rehabilitation and chronic-disease needs, supporting its leading revenue position.
Clinical conditions relevant to respiratory rehabilitation are prevalent across several Asia-Pacific markets. COPD prevalence was estimated at 14.5% among Australian adults aged 40 years and older, while a 2025 meta-analysis estimated pooled COPD prevalence in Chinese adults aged 40 years and older at 12.1%, with subgroup estimates ranging from 4.8% to 23.7%. Japan also presents a defined sports-rehabilitation opportunity: 50.01% of 10,998 collegiate athletes reported a sports injury during the prior year. These distinct demand settings favor differentiated channel strategies rather than a uniform regional product offer.
Latin America
Latin America represented 6.91% of global revenue in 2025, or approximately USD 21.18 million. Brazil, Mexico, and Argentina comprise the regional country scope. Brazil offers the region's clearest policy-related support for complementary care, as its Unified Health System and National Policy on Integrative and Complementary Practices incorporate acupuncture and related practices in chronic-pain management. [8]Pan American Health Organization, Webinar: Strengthening and Integrating TCIM in Health Systems, January 2023, paho.org
Brazil's August 2024 clinical guidance also cited acupuncture and auriculotherapy as effective options for reducing pain in adults and older people. This integration can support institutional demand where implementation is accompanied by practitioner availability and procurement processes. Mexico and Argentina expand the addressable regional footprint, but country-level development will remain dependent on local care pathways and provider capacity.
Middle East and Africa
The Middle East and Africa accounted for 4.61% of global market revenue in 2025, equivalent to approximately USD 14.13 million. Saudi Arabia, South Africa, and the UAE comprise the regional country scope. Saudi Arabia's chronic-disease profile provides a relevant demand backdrop: the SHINE 2023 survey reported hypertension prevalence of 16.1%, diabetes prevalence of 13.0%, obesity prevalence of 32.8%, and multimorbidity of approximately 10%.
The region's market opportunity is likely to develop unevenly. Saudi Arabia's disease burden and health-system investment can support demand for complementary pain and rehabilitation services, while uptake in South Africa and the UAE will depend on practitioner availability, regulatory treatment of acupuncture services, and the integration of complementary care into existing provider networks. Obesity-related health pressures are also material in Saudi Arabia, where reported prevalence has reached 35.6% in available evidence.
GMI Analyst View
Asia Pacific's leadership reflects more than regional scale. Its position is reinforced by established treatment familiarity and a broad mix of chronic, respiratory-rehabilitation, and sports-injury demand. China and Australia illustrate the relevance of COPD-related rehabilitation evidence, while Japan's collegiate injury prevalence points to a different, more sports-focused route to needle consumption. Suppliers need region-specific portfolio and distribution choices rather than a single Asia-Pacific operating model.
North America and Europe offer sizable pain-management demand but face greater exposure to reimbursement design. Brazil stands apart within Latin America because public-system integration of complementary practices can create a more institutionalized route to adoption. Across the Middle East and Africa, chronic-disease prevalence establishes a potential demand base, but commercial conversion will depend on healthcare infrastructure and the formal role accorded to acupuncture in care delivery.
Acupuncture Needles Market Share & Competitive Landscape
The competitive landscape includes 3B Scientific GmbH, AcuMedic Ltd, asia-med GmbH, SEIRIN, Dana Medical Co, Boen Healthcare Co Ltd, Suzhou Hualun, WUXI JIAJIAN MEDICAL DEVICES CO LTD, Suzhou Zhongjing Life & Science Technology Co. Ltd, Shinylink (Shanghai) Industrial Inc, MeyerDC, and Phoenix Medical. SEIRIN, Suzhou Zhongjing Life & Science Technology, Boen Healthcare Co. Ltd, 3B Scientific, and Suzhou Hualun collectively account for an estimated 80% share of the market.
SEIRIN Corporation
SEIRIN's competitive positioning is supported by advanced production methods, quality standards, and operations spanning Japan, Germany, China, and the U.S. Its J-Type product emphasizes stainless-steel construction, sterile disposable use, and patient-comfort features intended to support gentle insertion. The company's entry into non-invasive acupressure through PY-Zero also indicates an effort to participate in adjacent treatment formats rather than relying exclusively on conventional needle products.
Suzhou Zhongjing Life & Science Technology
Suzhou Zhongjing Life & Science Technology is positioned as an experienced manufacturer with internationally certified operations and standardized production processes. Its relevance to the market lies in the ability to serve international demand with consistent product quality and scalable manufacturing. In a market where sterile disposable formats are expanding, standardized production can be a meaningful basis for maintaining distributor and institutional relationships.
Boen Healthcare Co. Ltd
Boen Healthcare Co. Ltd operates as a comprehensive manufacturer with a structured supply chain and customized production capabilities. Customization is commercially relevant where distributors and private-label customers require differentiated handle designs, packaging formats, or needle specifications. The company's supply-chain discipline can also support responsiveness across markets with varying practitioner preferences and procurement requirements.
Recent Industry Developments
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Question(FAQ) :
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →